Tanespimycin (17-AAG)

For research use only.

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

61 publications

Tanespimycin (17-AAG) Chemical Structure

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 287 In stock
USD 97 In stock
USD 297 In stock
USD 797 In stock
USD 1337 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Tanespimycin (17-AAG) has been cited by 61 publications

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.
Features Displays very low toxicity toward normal cells.
Targets
HSP90 [1]
(Cell-free assay)
5 nM
In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. [1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. [2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3OyfWlEPTB;MD6wNFA{ODNizszN M4DWT3NCVkeHUh?=
IST-MEL1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLHTWM2OD1yLkCwNFQxPyEQvF2= MVjTRW5ITVJ?
NCI-SNU-1 MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jnZWlEPTB;MD6wNFIxPyEQvF2= NFH1cGRUSU6JRWK=
FADU NUC4d4Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzWTWM2OD1yLkCwNlA6KM7:TR?= M1zMS3NCVkeHUh?=
C32 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fHXGlEPTB;MD6wNFMxPCEQvF2= MXHTRW5ITVJ?
D-566MG NXfISVBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TtWmlEPTB;MD6wNFM6KM7:TR?= M{[1XHNCVkeHUh?=
LXF-289 NEDNdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXFOHdKSzVyPUCuNFA1OTlizszN MoXIV2FPT0WU
HGC-27 NH\O[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMEC1NUDPxE1? M1XtRnNCVkeHUh?=
RPMI-7951 NIDoT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITwXoVKSzVyPUCuNFA4OTdizszN Mkf1V2FPT0WU
HSC-3 NYm3XGw6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMEC5Nlkh|ryP NWTvfpA{W0GQR1XS
MIA-PaCa-2 M3jrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPzRXlWUUN3ME2wMlAyODB7IN88US=> M2HRVnNCVkeHUh?=
KS-1 MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn31TWM2OD1yLkCxN|U2KM7:TR?= M1Tk[3NCVkeHUh?=
CAL-51 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HpRmlEPTB;MD6wNVQxPSEQvF2= M2PEd3NCVkeHUh?=
MDA-MB-361 NGHMfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLQTWM2OD1yLkCxOFk2KM7:TR?= NInnZ41USU6JRWK=
TI-73 NIOwXGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMEG3PVYh|ryP M3zBRnNCVkeHUh?=
AGS M1XpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwMEG5N|gh|ryP MX;TRW5ITVJ?
NCI-H460 NYnObZlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPzRY1KSzVyPUCuNFE6PzRizszN NYnrV3FZW0GQR1XS
A204 MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPkdVZTUUN3ME2wMlAzOjR7IN88US=> NE\xb2hUSU6JRWK=
CHL-1 NXH4[HI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMEKyOVEh|ryP MkTJV2FPT0WU
DU-4475 M4nxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHmSHdKSzVyPUCuNFIzPjFizszN NI\nc2xUSU6JRWK=
CGTH-W-1 NWflVpQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMEKzOFkh|ryP MXXTRW5ITVJ?
HCC2218 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMEK0PVQh|ryP M1;NOXNCVkeHUh?=
A2780 NU\rZmdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LvcGlEPTB;MD6wNlU{OSEQvF2= M1zUfXNCVkeHUh?=
NCI-H720 M3;NZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L3b2lEPTB;MD6wNlU1PiEQvF2= MUDTRW5ITVJ?
NCI-N87 M2fJfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzQTWM2OD1yLkCyOVk{KM7:TR?= NV;1[IpMW0GQR1XS
CHP-212 NITvNZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMEK2Nlgh|ryP NUPNNVY{W0GQR1XS
NCI-H23 NG\vcpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jPPGlEPTB;MD6wNlY3PSEQvF2= NGPHeGxUSU6JRWK=
D-263MG M{DjTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETqZVJKSzVyPUCuNFI4QDZizszN M2DFUXNCVkeHUh?=
ME-180 MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn32TWM2OD1yLkCyPFkyKM7:TR?= M37CTnNCVkeHUh?=
SW982 M{Sy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnQTWM2OD1yLkCyPVk6KM7:TR?= Ml:xV2FPT0WU
OE19 M1zLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMEOwO|ch|ryP NWLPNnM{W0GQR1XS
SK-LU-1 M1zyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4WwcWlEPTB;MD6wN|A5OiEQvF2= MYPTRW5ITVJ?
H4 NFvrTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjmTWM2OD1yLkCzNFkh|ryP NUn2fXliW0GQR1XS
HT-144 M2HqNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrJSVBKSzVyPUCuNFMxQTNizszN MVHTRW5ITVJ?
SK-UT-1 NXT2eYR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvnc3RuUUN3ME2wMlA{OTd6IN88US=> NVHpcoo1W0GQR1XS
D-336MG Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvOTWM2OD1yLkCzN|A6KM7:TR?= Ml3VV2FPT0WU
MDA-MB-175-VII MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf4RXJKSzVyPUCuNFM{PTRizszN NF\VSVBUSU6JRWK=
GAMG Mn31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMEO0N|Uh|ryP NX\5[Wd5W0GQR1XS
CP50-MEL-B MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:zfmlEPTB;MD6wN|Q2KM7:TR?= MkfDV2FPT0WU
OVCAR-5 NXywZmxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\2UnNqUUN3ME2wMlA{PDhizszN NFj5T2JUSU6JRWK=
SK-MES-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPzdY4yUUN3ME2wMlA{PjB4IN88US=> NYnUT2tvW0GQR1XS
VM-CUB-1 NH\W[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrNTWM2OD1yLkCzOlU4KM7:TR?= NWW3RYI2W0GQR1XS
WM-115 M1fadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;2RpZCUUN3ME2wMlA{PzZ{IN88US=> M{fIWXNCVkeHUh?=
DSH1 NIPnV|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfwfGhKSzVyPUCuNFM5ODdizszN MkTCV2FPT0WU
Becker NIP6OlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH22eZhKSzVyPUCuNFM5QDVizszN NES5TGFUSU6JRWK=
SW962 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfmS|RtUUN3ME2wMlA{QTR3IN88US=> MYDTRW5ITVJ?
TYK-nu M{jTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDETWM2OD1yLkCzPVg2KM7:TR?= NF63U2pUSU6JRWK=
HO-1-N-1 NGK3dGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPmW|VKSzVyPUCuNFQxOjFizszN NHHTXYJUSU6JRWK=
T98G NFrKbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMESxNFMh|ryP NFnwUpVUSU6JRWK=
ACN MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMESxOlIh|ryP NWeweIlXW0GQR1XS
SW780 M2nrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfjTWM2OD1yLkC0NlA{KM7:TR?= Mny5V2FPT0WU
Detroit562 M4nQTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XUTGlEPTB;MD6wOFI{QSEQvF2= MWrTRW5ITVJ?
BB49-HNC NXr1VYpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHZWo1NUUN3ME2wMlA1OjR|IN88US=> MnfyV2FPT0WU
HN NH;lXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XZOmlEPTB;MD6wOFI4OiEQvF2= Mn\mV2FPT0WU
H9 MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrIZXIxUUN3ME2wMlA1OzdzIN88US=> NULqUHQ2W0GQR1XS
VA-ES-BJ MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fDVWlEPTB;MD6wOFQ1PyEQvF2= NYTYe45oW0GQR1XS
MEL-JUSO MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK1WG1KSzVyPUCuNFQ1PzVizszN NEjEXotUSU6JRWK=
BT-474 NE\3TWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\wOlhKSzVyPUCuNFQ2KM7:TR?= MnW1V2FPT0WU
CaR-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP5TWM2OD1yLkC0OVQ6KM7:TR?= NES3XGxUSU6JRWK=
PSN1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMES2NFMh|ryP NGXJcWZUSU6JRWK=
KYSE-510 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz2bHhKSzVyPUCuNFQ3PDlizszN MWLTRW5ITVJ?
KP-4 NX7HbGxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMES3OVMh|ryP NVnGbXJGW0GQR1XS
KYSE-410 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uwe2lEPTB;MD6wOFc4OiEQvF2= MlmzV2FPT0WU
G-402 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHLeo9uUUN3ME2wMlA1Pzh7IN88US=> MnzTV2FPT0WU
DOK NIHw[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLteohKSzVyPUCuNFQ6ODJizszN NITKNnNUSU6JRWK=
COR-L88 NVXlPWI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnydHZKSzVyPUCuNFQ6OTJizszN MXfTRW5ITVJ?
SKG-IIIa NWDiRYJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPRTWM2OD1yLkC0PVg3KM7:TR?= NELHXnFUSU6JRWK=
AN3-CA NUG1RpFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjXOoN7UUN3ME2wMlA2KM7:TR?= MYHTRW5ITVJ?
SW48 MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTMU452UUN3ME2wMlA2ODN7IN88US=> NU\kUIhrW0GQR1XS
YKG-1 MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEntd5BKSzVyPUCuNFUxPzFizszN MkPaV2FPT0WU
KYSE-150 NX\Y[|g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEWyN|Uh|ryP MYDTRW5ITVJ?
HuO-3N1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILKZ2lKSzVyPUCuNFUzOzdizszN MkPaV2FPT0WU
LB1047-RCC NYrhNGx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm3TWM2OD1yLkC1Nlk3KM7:TR?= NUjsNVdUW0GQR1XS
NCI-H2030 NHf6VY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nlcWlEPTB;MD6wOVQyPCEQvF2= MoTjV2FPT0WU
YH-13 M{KzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnjTWM2OD1yLkC1O|IzKM7:TR?= MWPTRW5ITVJ?
5637 MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXmUYRKSzVyPUCuNFU4PCEQvF2= M1zKPXNCVkeHUh?=
LOXIMVI Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjiTWM2OD1yLkC1PFczKM7:TR?= NGDxRYxUSU6JRWK=
GT3TKB M2jPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMEW5OFIh|ryP MYnTRW5ITVJ?
TCCSUP NULDRpk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm3XHhKSzVyPUCuNFU6PjRizszN NHf5NIJUSU6JRWK=
EPLC-272H NH\YdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fWW2lEPTB;MD6wOlIxPSEQvF2= MoTBV2FPT0WU
LU-99A NFPGb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TyV2lEPTB;MD6wOlI{PyEQvF2= MYHTRW5ITVJ?
NCI-H1755 NEns[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwME[zOFEh|ryP NGLN[ZVUSU6JRWK=
KM12 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwME[zOFgh|ryP NUfENmhbW0GQR1XS
SF295 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3lTWM2OD1yLkC2OFUzKM7:TR?= NYHsSWtCW0GQR1XS
MZ2-MEL M3y5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P6U2lEPTB;MD6wOlU2OyEQvF2= MVzTRW5ITVJ?
HEC-1 Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjqZo1mUUN3ME2wMlA3PTh6IN88US=> NV3Db4RjW0GQR1XS
SW684 NFLZbWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnKxTWM2OD1yLkC2OVkyKM7:TR?= MlGyV2FPT0WU
SF539 NWHCPWw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4C5SWlEPTB;MD6wOlY5OSEQvF2= NU\Kcm9FW0GQR1XS
GMS-10 M33UeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\VW3RiUUN3ME2wMlA3Pjl7IN88US=> MXPTRW5ITVJ?
MV-4-11 NHLHN|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrKTWM2OD1yLkC2PFA{KM7:TR?= NYOzRnpDW0GQR1XS
HT-29 MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PWW2lEPTB;MD6wOlkyQSEQvF2= NEDjc45USU6JRWK=
23132-87 NYTPV5I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLp[2VKSzVyPUCuNFY6PSEQvF2= NEDPfXRUSU6JRWK=
SW620 M3rD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3iybmlEPTB;MD6wO|AzPiEQvF2= NXLkSWRGW0GQR1XS
HCC1806 M{LMU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlS3TWM2OD1yLkC3NVMyKM7:TR?= M3zNZ3NCVkeHUh?=
Hs-578-T MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMEeyNFgh|ryP MXTTRW5ITVJ?
A2058 NVLieXJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DnbmlEPTB;MD6wO|IzQCEQvF2= MUHTRW5ITVJ?
MEL-HO Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHaTWM2OD1yLkC3NlU2KM7:TR?= M2fUdnNCVkeHUh?=
HCC2998 M{fUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorkTWM2OD1yLkC3N|Q4KM7:TR?= MW\TRW5ITVJ?
HuO9 NIHMeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvl[FhKSzVyPUCuNFc2QDlizszN MVHTRW5ITVJ?
CAL-39 M36yfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\WNmlEPTB;MD6wO|c3PiEQvF2= Mnu3V2FPT0WU
M14 M{DBcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTWTWM2OD1yLkC3PVE{KM7:TR?= MnfCV2FPT0WU
BFTC-909 NET2SVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHPboJKSzVyPUCuNFc6PjlizszN MlzWV2FPT0WU
TE-11 NEDxb25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnUOGRFUUN3ME2wMlA4QTl4IN88US=> NFe1blFUSU6JRWK=
TGBC1TKB MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjZSmNoUUN3ME2wMlA5ODR|IN88US=> M4i2RnNCVkeHUh?=
L-363 M1rkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3IbnRKSzVyPUCuNFgzODZizszN M3;IN3NCVkeHUh?=
A431 MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnrW5FKSzVyPUCuNFgzOSEQvF2= Mli3V2FPT0WU
MKN45 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH4bZNKUUN3ME2wMlA5OjF7IN88US=> NHPDemxUSU6JRWK=
HT-1080 M1HyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMEi0N|kh|ryP NIDIfXpUSU6JRWK=
OVCAR-8 M1X1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\PcGlEPTB;MD6wPFYzOiEQvF2= MX7TRW5ITVJ?
LCLC-97TM1 NXzIR4kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zrZmlEPTB;MD6wPFczQCEQvF2= NHu3O2xUSU6JRWK=
M059J MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TZRWlEPTB;MD6wPVAzPyEQvF2= NIf0WWFUSU6JRWK=
SK-MEL-2 NEjHNJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwMEmwOkDPxE1? NIr0N4RUSU6JRWK=
TE-1 NWHzOIxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX0SZVJUUN3ME2wMlA6OjB2IN88US=> MY\TRW5ITVJ?
KYSE-180 M2jodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDZOJZKSzVyPUCuNFkzPjJizszN M2rkUnNCVkeHUh?=
D-247MG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m1TGlEPTB;MD6wPVQ2PSEQvF2= MVzTRW5ITVJ?
8-MG-BA Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XqZ2lEPTB;MD6wPVQ4OiEQvF2= MoDuV2FPT0WU
NCI-H1792 MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrxTWM2OD1yLkC5OlE5KM7:TR?= NH3VVHZUSU6JRWK=
MCF7 MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7RS2dKSzVyPUCuNFk3PzdizszN M{WyXnNCVkeHUh?=
NCI-H2122 NWXHO2ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMEm3OFUh|ryP MY\TRW5ITVJ?
EFO-27 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fjPWlEPTB;MD6wPVk6PyEQvF2= NUTMdFBlW0GQR1XS
LB2241-RCC NGP5Z4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K3V2lEPTB;MD6xNFA2PCEQvF2= MnPZV2FPT0WU
SN12C MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMUCxNFch|ryP MU\TRW5ITVJ?
A498 NFzjOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS0TWFKSzVyPUCuNVAyQCEQvF2= MnfTV2FPT0WU
PANC-03-27 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzuU5k3UUN3ME2wMlExOjh4IN88US=> Mn3nV2FPT0WU
NCI-H1581 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13CdWlEPTB;MD6xNFI6KM7:TR?= NEK5XoRUSU6JRWK=
U-87-MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DIUWlEPTB;MD6xNFMxPyEQvF2= MljOV2FPT0WU
G-401 Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLYTWM2OD1yLkGwN|U{KM7:TR?= NEThe4JUSU6JRWK=
SiHa NUnoT5p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnGxTWM2OD1yLkGwOFg3KM7:TR?= M1HYc3NCVkeHUh?=
U251 NEnIW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LqSWlEPTB;MD6xNFUzPSEQvF2= Ml6wV2FPT0WU
MMAC-SF NWqzZpVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjETWM2OD1yLkGwOVMyKM7:TR?= NE\OPWlUSU6JRWK=
BB65-RCC MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fiV2lEPTB;MD6xNFU2PCEQvF2= NHzB[mtUSU6JRWK=
NKM-1 M1:yWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33zcGlEPTB;MD6xNFY3PiEQvF2= NXvuc5JuW0GQR1XS
HD-MY-Z NIrlflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfQTWM2OD1yLkGwPFc{KM7:TR?= Ml7yV2FPT0WU
TGBC11TKB NV7zUo9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LWOmlEPTB;MD6xNFkxOyEQvF2= MVrTRW5ITVJ?
COLO-679 M3TscGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPIdlVKSzVyPUCuNVEzOTFizszN Mne5V2FPT0WU
TE-8 NXrScGk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rvemlEPTB;MD6xNVI3PCEQvF2= M4jMfXNCVkeHUh?=
SK-MEL-28 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfMbJBKSzVyPUCuNVE{OjFizszN M3nubnNCVkeHUh?=
SH-4 NHXLR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjvTWM2OD1yLkGxN|U3KM7:TR?= MXXTRW5ITVJ?
KALS-1 NG\6N5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMUGzPVMh|ryP NIf5O3lUSU6JRWK=
RKO M12xVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;tTWM2OD1yLkGxO|Y1KM7:TR?= MnHTV2FPT0WU
OMC-1 M3XTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX0fmZTUUN3ME2wMlEyPzl5IN88US=> M3vBOXNCVkeHUh?=
BT-549 MkmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\UXHVxUUN3ME2wMlEyPzl7IN88US=> M2DLSHNCVkeHUh?=
NCI-H28 NES2TmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMUG4NVch|ryP MoPIV2FPT0WU
RXF393 MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIG2[ZpKSzVyPUCuNVE6QDJizszN M2LBVnNCVkeHUh?=
COLO-829 NH\2d3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMUKwNFUh|ryP MVzTRW5ITVJ?
HMV-II MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMUKwNkDPxE1? M3L1WnNCVkeHUh?=
SW1990 NGK4NZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwMUKxOVch|ryP NYCxWHBQW0GQR1XS
NCI-H1437 NEjLXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH62TnJKSzVyPUCuNVIyPTdizszN NXe3VmUzW0GQR1XS
SNB75 Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLCTWM2OD1yLkGyNVY6KM7:TR?= M165b3NCVkeHUh?=
EW-3 M2DoO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\6TWM2OD1yLkGyOlYyKM7:TR?= MUnTRW5ITVJ?
SAS M4j2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi5TWM2OD1yLkGyOlkh|ryP NFziN5JUSU6JRWK=
NCI-H1666 NYnpb3hQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HMSmlEPTB;MD6xNlc4PCEQvF2= MY\TRW5ITVJ?
A375 M1O3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rCZWlEPTB;MD6xNlc4QCEQvF2= MnnnV2FPT0WU
CAMA-1 MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\FTWFvUUN3ME2wMlEzQTJ2IN88US=> MX3TRW5ITVJ?
HuP-T4 NWDVeIVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;jeWlEPTB;MD6xNlk1OyEQvF2= MVnTRW5ITVJ?
NCI-H292 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi0XIlKSzVyPUCuNVMyOSEQvF2= M3nKeXNCVkeHUh?=
PC-14 M3rWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYS4NohrUUN3ME2wMlE{OjFzIN88US=> MYHTRW5ITVJ?
BPH-1 M1fG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLrWHVKSzVyPUCuNVM1OSEQvF2= NIryV5RUSU6JRWK=
GAK NEDib3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMUO1Olch|ryP MnHhV2FPT0WU
VMRC-RCZ MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMUO3OlIh|ryP M4Lzd3NCVkeHUh?=
SK-MEL-24 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjrOlNRUUN3ME2wMlE{QDdizszN Mln5V2FPT0WU
LB831-BLC MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMUO4PFMh|ryP MYnTRW5ITVJ?
NCI-H2452 NImyVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMUO5OVYh|ryP NFPG[FJUSU6JRWK=
RT-112 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTmPYpKSzVyPUCuNVQxOzVizszN NVvBdolkW0GQR1XS
GP5d MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXroW25TUUN3ME2wMlE1OTB2IN88US=> NE\xemhUSU6JRWK=
LC-2-ad NXXSPFRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37yfWlEPTB;MD6xOFEzOSEQvF2= M1HWfHNCVkeHUh?=
MPP-89 M3y5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\hVWlEPTB;MD6xOFEzPSEQvF2= NWDQWFdwW0GQR1XS
NUGC-3 MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW0TWM2OD1yLkG0OFc5KM7:TR?= MoToV2FPT0WU
GI-1 Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;xU3JKSzVyPUCuNVQ2PThizszN NEPnfnZUSU6JRWK=
HCC1419 NYjYR2ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMUS1O|Yh|ryP NEjjbpRUSU6JRWK=
SW1573 NYDZ[lVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrScHlVUUN3ME2wMlE1PzV6IN88US=> NVTxdpEyW0GQR1XS
NCI-H2347 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjtRpNKSzVyPUCuNVQ5OzlizszN M1XyNHNCVkeHUh?=
Mewo NIPW[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrEXGhKSzVyPUCuNVQ5QDlizszN NWfkWI1lW0GQR1XS
639-V MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XhdWlEPTB;MD6xOVAyOyEQvF2= NFTwe45USU6JRWK=
AsPC-1 NWrIdHI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL3[|dKSzVyPUCuNVUzOjVizszN M1OxU3NCVkeHUh?=
NCI-H1648 MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwMUWyN|Ih|ryP MXzTRW5ITVJ?
786-0 NUOzToJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDXTlVKSzVyPUCuNVU{QDFizszN MWXTRW5ITVJ?
ETK-1 MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fiZWlEPTB;MD6xOVkh|ryP NVrBSmE1W0GQR1XS
BxPC-3 M{S2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfCV2JKSzVyPUCuNVU6PjZizszN M2DreHNCVkeHUh?=
CAL-62 NYTQV5g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jIbWlEPTB;MD6xOlE3QSEQvF2= MYXTRW5ITVJ?
HCC1937 M3jvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne0TWM2OD1yLkG2Nlc2KM7:TR?= Mnz2V2FPT0WU
NCI-H1299 NVX0O|RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMU[yPFUh|ryP M1TNSXNCVkeHUh?=
SW1088 NX7VWm1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTlTWM2OD1yLkG2OFE{KM7:TR?= NFXlZWtUSU6JRWK=
FTC-133 MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfOTWM2OD1yLkG2OVQh|ryP NILqdpRUSU6JRWK=
OC-314 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvmTWM2OD1yLkG2Olkh|ryP NXq5XmFSW0GQR1XS
SCC-9 MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCwXZVRUUN3ME2wMlE3PzF4IN88US=> NXzrWVl1W0GQR1XS
HT-1376 MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfwUmVyUUN3ME2wMlE3QTN4IN88US=> NGeyRVhUSU6JRWK=
U-2-OS M3zST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37kdWlEPTB;MD6xO|E4OyEQvF2= MorEV2FPT0WU
COLO-824 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDYTWM2OD1yLkG3Nlk1KM7:TR?= MnzTV2FPT0WU
BB30-HNC MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MomzTWM2OD1yLkG3N|Mh|ryP Ml7HV2FPT0WU
NCI-H2087 M1jBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfpcVB1UUN3ME2wMlE4OzZ6IN88US=> Mn60V2FPT0WU
NCI-H2170 NWPoOlNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMUe1N|Yh|ryP NWXZfJVqW0GQR1XS
SK-OV-3 M{\BeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwMUe1O|Eh|ryP MmexV2FPT0WU
MZ7-mel NHXzTIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\1U|dKSzVyPUCuNVc3PDlizszN NFPuVnlUSU6JRWK=
NCI-H650 NFrQXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[4TWM2OD1yLkG3OlgzKM7:TR?= M{DLcnNCVkeHUh?=
KOSC-2 NFfGUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3uwRmlEPTB;MD6xO|c{PCEQvF2= NHLWd3FUSU6JRWK=
SCC-4 NGrZR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPSPYxKSzVyPUCuNVc4PzdizszN MUnTRW5ITVJ?
MDA-MB-157 MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3UTWM2OD1yLkG4NFgzKM7:TR?= NGT4XVFUSU6JRWK=
KYSE-520 NU[wWppVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXNfW9NUUN3ME2wMlE5OiEQvF2= NVzSdZFWW0GQR1XS
LK-2 NHHmd4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\Fe5BKSzVyPUCuNVg{ODNizszN NEPSZo9USU6JRWK=
KNS-81-FD MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rwTmlEPTB;MD6xPFM6PCEQvF2= M2P5N3NCVkeHUh?=
IGROV-1 M4PqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXO4bYxyUUN3ME2wMlE5PDR|IN88US=> M2nYTHNCVkeHUh?=
DEL MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwMUi0OUDPxE1? MlPJV2FPT0WU
NCI-H1395 NEm1SZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMUi2PFIh|ryP MoPEV2FPT0WU
JEG-3 NVy5cHJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfBTWM2OD1yLkG4O|A2KM7:TR?= NWq4WWhkW0GQR1XS
BCPAP MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD4TWM2OD1yLkG4PFczKM7:TR?= MorkV2FPT0WU
CAL-27 NYrDeGRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXIS|JKSzVyPUCuNVkxOjJizszN NFfmOmZUSU6JRWK=
RD MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwMUmxNVMh|ryP M2C5[HNCVkeHUh?=
RVH-421 NIm3WXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfjWWx4UUN3ME2wMlE6OTF4IN88US=> MVPTRW5ITVJ?
Capan-2 M3fuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTXU5RKSzVyPUCuNVkzPTZizszN NGP6b4RUSU6JRWK=
COLO-680N M2fkV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW2dm9KSzVyPUCuNVk{PjRizszN NGHZNoVUSU6JRWK=
NCI-H1650 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMkCwOVch|ryP MW\TRW5ITVJ?
SBC-5 MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;3epJKUUN3ME2wMlIxOTF6IN88US=> NHG0XIJUSU6JRWK=
U031 NEjsd|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7SNXhKSzVyPUCuNlA2PDdizszN NV\1Xop[W0GQR1XS
S-117 Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjzTWM2OD1yLkKwOVY1KM7:TR?= MWrTRW5ITVJ?
DoTc2-4510 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLHZYFxUUN3ME2wMlIxPzZ7IN88US=> Mnj3V2FPT0WU
AM-38 M1Lq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrrU3RpUUN3ME2wMlIxQDR6IN88US=> NFG5cWtUSU6JRWK=
A172 NXnHU|BvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF76cVRKSzVyPUCuNlExOjJizszN MWHTRW5ITVJ?
HPAF-II NYTIb252T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMkGyOlQh|ryP M3PhfnNCVkeHUh?=
769-P Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMkGyPEDPxE1? M3rnS3NCVkeHUh?=
MFE-280 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMkGyPVgh|ryP NY\yO3h4W0GQR1XS
TE-9 NFjSSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf3UVNKSzVyPUCuNlE4QDZizszN NX75UIVbW0GQR1XS
C2BBe1 NYKyO2FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXFXYd3UUN3ME2wMlIzOTlizszN NFnUPHlUSU6JRWK=
EoL-1-cell MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELmTG1KSzVyPUCuNlIzODNizszN NU\MdpM6W0GQR1XS
G-361 Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFThXppKSzVyPUCuNlI3QDJizszN NFP3cXNUSU6JRWK=
KYSE-270 NIixXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMkOwPFQh|ryP MWDTRW5ITVJ?
TK10 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LlTmlEPTB;MD6yN|EyPyEQvF2= MVzTRW5ITVJ?
ML-2 M1\BXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLZTWM2OD1yLkKzNVE6KM7:TR?= MoTjV2FPT0WU
MHH-ES-1 NF[z[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\SN2lEPTB;MD6yN|Y5OSEQvF2= M3LTXnNCVkeHUh?=
BHY NYjwb3ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTRTWM2OD1yLkKzOlkyKM7:TR?= MkL5V2FPT0WU
LS-513 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq2TGh7UUN3ME2wMlI{QTZzIN88US=> M4HUS3NCVkeHUh?=
COLO-678 M{jvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIO4eXdKSzVyPUCuNlQxPDRizszN Mn7nV2FPT0WU
NCI-H747 MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjpW3VKSzVyPUCuNlQyPjlizszN MlPtV2FPT0WU
K5 NYnWfZJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzV[VZ1UUN3ME2wMlI1OzhizszN M2TL[XNCVkeHUh?=
OS-RC-2 NGXlNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr0eIFKSzVyPUCuNlQ2ODlizszN MYnTRW5ITVJ?
KINGS-1 M2L6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjlTWM2OD1yLkK0OVI6KM7:TR?= Mln0V2FPT0WU
SCC-25 MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfYXpFKSzVyPUCuNlQ2PjNizszN M1ryb3NCVkeHUh?=
CAPAN-1 NF7YUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPjTWM2OD1yLkK0O|g{KM7:TR?= MlLJV2FPT0WU
ESS-1 M1P4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK0dYJ7UUN3ME2wMlI1QDB3IN88US=> NVXyO|dRW0GQR1XS
TE-6 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nuOmlEPTB;MD6yOVc2KM7:TR?= NUHVfJhTW0GQR1XS
LB2518-MEL M2HXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjxeVN4UUN3ME2wMlI2Pzd5IN88US=> MUDTRW5ITVJ?
COLO-800 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT6TWM2OD1yLkK1PFEzKM7:TR?= MoTKV2FPT0WU
LU-134-A NYO1elY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwMk[xN|Yh|ryP MmnmV2FPT0WU
NCI-H1155 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTvTWM2OD1yLkK2NVYzKM7:TR?= NITi[nJUSU6JRWK=
MFM-223 NGPQSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMk[zOlMh|ryP MVLTRW5ITVJ?
HTC-C3 NHzUUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f6OGlEPTB;MD6yOlUxPiEQvF2= MYTTRW5ITVJ?
HCT-116 M2e1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\ZdWlEPTB;MD6yOlU6QSEQvF2= M2jVSHNCVkeHUh?=
Ca-Ski MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjpNmI4UUN3ME2wMlI3Pjd6IN88US=> MYHTRW5ITVJ?
SBC-1 NFjmcVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\kflBKSzVyPUCuNlY4PDJizszN MnXmV2FPT0WU
NB69 NGjhVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoewTWM2OD1yLkK3NFg4KM7:TR?= MVvTRW5ITVJ?
J82 NYPTUI8xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnsSJdLUUN3ME2wMlI4OjZ3IN88US=> MlzvV2FPT0WU
U-118-MG Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFy4ZYVKSzVyPUCuNlc2PzlizszN M37qWnNCVkeHUh?=
NCI-H1355 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnZO4VKSzVyPUCuNlgxPzRizszN NY\LZYI3W0GQR1XS
NCI-H1048 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HjTmlEPTB;MD6yPFk2PiEQvF2= Ml3zV2FPT0WU
SW954 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzPOlBLUUN3ME2wMlI6OjJ5IN88US=> NFjmPVRUSU6JRWK=
NMC-G1 Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInwdmRKSzVyPUCuNlkzPzdizszN NGnQcXpUSU6JRWK=
SW1710 NGL4RlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ixTWlEPTB;MD6yPVQ6PCEQvF2= MlrQV2FPT0WU
KY821 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fEfGlEPTB;MD6yPVg4OiEQvF2= MX3TRW5ITVJ?
HCC38 M2nER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnuzTWM2OD1yLkOwNFc5KM7:TR?= MlrTV2FPT0WU
NCI-SNU-5 MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwM{C1OEDPxE1? NULUPGZnW0GQR1XS
ES8 Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TsRmlEPTB;MD6zNFc5PCEQvF2= MoT1V2FPT0WU
COLO-792 MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwM{GyOVEh|ryP MVrTRW5ITVJ?
BFTC-905 M3;mVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor1TWM2OD1yLkOxOVIyKM7:TR?= MlfRV2FPT0WU
ChaGo-K-1 NU\IV2t[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrrRpZnUUN3ME2wMlMyPzF3IN88US=> M33CXHNCVkeHUh?=
Daoy M2fBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j6dGlEPTB;MD6zNVczOyEQvF2= M2HnWXNCVkeHUh?=
SJSA-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LnUmlEPTB;MD6zNVg1PyEQvF2= MVrTRW5ITVJ?
KNS-62 M2\Wdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Oyb2lEPTB;MD6zNlA5QCEQvF2= Mn;sV2FPT0WU
CAKI-1 NYriTox[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe2UldKSzVyPUCuN|IyOTFizszN NGj3S29USU6JRWK=
UACC-62 NFzZd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml30TWM2OD1yLkOyNlI4KM7:TR?= NYTwPYhRW0GQR1XS
HuCCT1 NH;4dVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnYWWxKSzVyPUCuN|IzQDNizszN NUPyc5NOW0GQR1XS
CTB-1 NWLpV3pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwM{K3OVMh|ryP NVTDVZZRW0GQR1XS
NTERA-S-cl-D1 M1;uNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwM{K4N|Yh|ryP NIjJZYNUSU6JRWK=
T-24 M2jhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfaZnFUUUN3ME2wMlM{OTV7IN88US=> NYLIZXVkW0GQR1XS
KYSE-70 NFToNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XJWmlEPTB;MD6zN|I5OyEQvF2= M4P6SnNCVkeHUh?=
SW626 M3fzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwM{O1N|Ih|ryP M3rvR3NCVkeHUh?=
LB996-RCC MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD5cXhMUUN3ME2wMlM{PjF7IN88US=> MXnTRW5ITVJ?
DMS-273 NF7lcYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwM{O5NVYh|ryP M{nVSnNCVkeHUh?=
SW1783 MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwM{O5PVch|ryP M3rB[3NCVkeHUh?=
KU812 NUG3coJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7QNYxPUUN3ME2wMlM1ODN6IN88US=> Mn7DV2FPT0WU
HSC-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TPdWlEPTB;MD6zOFA2OyEQvF2= NYjiNY82W0GQR1XS
A3-KAW NFHiTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXnTWM2OD1yLkO0NVYzKM7:TR?= NETyOJZUSU6JRWK=
COLO-684 NHKzfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\3OWlEPTB;MD6zOFUxOSEQvF2= NUTKV5BIW0GQR1XS
NCI-H2405 NV\sToJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHDVZBHUUN3ME2wMlM1PjNzIN88US=> MUfTRW5ITVJ?
NCI-H2228 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLsb2dKSzVyPUCuN|U{PTdizszN NULzOWtKW0GQR1XS
NB13 NEPzNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPLXHBKSzVyPUCuN|Y5OjlizszN NHrWcZFUSU6JRWK=
no-11 NWXoU4o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LsSGlEPTB;MD6zOlk2KM7:TR?= M37Hb3NCVkeHUh?=
DK-MG NEixVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmWwTWM2OD1yLkO3NVg5KM7:TR?= MWHTRW5ITVJ?
NBsusSR MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\pZlBKSzVyPUCuN|czQDVizszN M1HlWnNCVkeHUh?=
KP-N-YS MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwM{e0OlMh|ryP NXLneGpuW0GQR1XS
CFPAC-1 NWPqeFRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;zTWM2OD1yLkO3OVE5KM7:TR?= NGjxO5hUSU6JRWK=
KARPAS-45 NEHhPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwM{e4OlIh|ryP Mlf1V2FPT0WU
NCI-H1793 NGH5VZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwM{i1NUDPxE1? Mn7IV2FPT0WU
HCE-T MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP0[45YUUN3ME2wMlM5PjB|IN88US=> M3;3V3NCVkeHUh?=
NCI-H520 Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2SzdGlEPTB;MD6zPFcxOyEQvF2= Mn;kV2FPT0WU
HCC2157 Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojjTWM2OD1yLkO4O|gyKM7:TR?= NEXjZXRUSU6JRWK=
EW-18 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f6VmlEPTB;MD6zPFk1OSEQvF2= MnL2V2FPT0WU
RO82-W-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:1TWM2OD1yLkO5Olk6KM7:TR?= NHLMS4lUSU6JRWK=
HuP-T3 NYSxT3dbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDaWJdYUUN3ME2wMlQxOTR|IN88US=> M4LZVHNCVkeHUh?=
PANC-10-05 NVjpXlJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nQfGlEPTB;MD60NVE4KM7:TR?= MmfIV2FPT0WU
NCI-H1703 NIP5bmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fIdmlEPTB;MD60NVQ1PiEQvF2= MmHXV2FPT0WU
TE-10 NFXMSFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moe2TWM2OD1yLkSxOFQ4KM7:TR?= NWHTRohrW0GQR1XS
HOS MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ryTWlEPTB;MD60NVY5OiEQvF2= NVvEVXVDW0GQR1XS
LN-405 NY\VbXptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zXSWlEPTB;MD60NVY5PyEQvF2= NFXXbllUSU6JRWK=
A427 NFXzcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH4S5FpUUN3ME2wMlQyQThzIN88US=> NYPrUXhwW0GQR1XS
CAL-12T NXHiTIFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3njfGlEPTB;MD60Nlc5KM7:TR?= NHzafnRUSU6JRWK=
SW756 NFXxVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j2N2lEPTB;MD60OFE5OyEQvF2= MVPTRW5ITVJ?
YAPC NE\hbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwNEWwPEDPxE1? Ml3nV2FPT0WU
GOTO Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG3RZRKSzVyPUCuOFUyPiEQvF2= NHXVbZNUSU6JRWK=
C3A NUH0dHFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjnTolrUUN3ME2wMlQ2PDN5IN88US=> MlHHV2FPT0WU
UM-UC-3 NYfVNoI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fLXGlEPTB;MD60OVQ4KM7:TR?= M1mwUXNCVkeHUh?=
NCI-H1573 NGi3R41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwNEW1Olkh|ryP MkPUV2FPT0WU
LS-411N MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzOWJFVUUN3ME2wMlQ3PTJ5IN88US=> MXXTRW5ITVJ?
COR-L23 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfETWM2OD1yLkS2O|Y1KM7:TR?= NEi2[XNUSU6JRWK=
HCE-4 MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTTTWM2OD1yLkS3OFQ3KM7:TR?= MVrTRW5ITVJ?
NCI-H2291 M2XRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzFd2ZKSzVyPUCuOFc5QTZizszN NH7iPVVUSU6JRWK=
A101D Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXr4RVRbUUN3ME2wMlQ5ODV|IN88US=> NXrTOVV[W0GQR1XS
HT-3 MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTUTWM2OD1yLkS4NlE4KM7:TR?= M2[zSnNCVkeHUh?=
HOP-62 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwNEm4OlUh|ryP MYfTRW5ITVJ?
PC-3 M1fNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvQTWM2OD1yLkWxOVA4KM7:TR?= NWSxcpRzW0GQR1XS
CTV-1 M1jyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrZUYRQUUN3ME2wMlUzPjZ7IN88US=> M4XGbnNCVkeHUh?=
PANC-08-13 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn1TWM2OD1yLkWzNVc4KM7:TR?= NFjYNm1USU6JRWK=
CAL-120 NEnVfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\PNllnUUN3ME2wMlU{Ozl7IN88US=> NGGy[IpUSU6JRWK=
UMC-11 M3LTOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwNUWyN|Qh|ryP MkXTV2FPT0WU
MSTO-211H NFS5VI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwNUW3OlIh|ryP NHznZVJUSU6JRWK=
NCI-H2126 NVjJXmxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XDTmlEPTB;MD61OlgyPSEQvF2= M1XKcXNCVkeHUh?=
SNU-C2B NWHu[ZFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP6UWl6UUN3ME2wMlU4QTd5IN88US=> NH7MTpBUSU6JRWK=
DBTRG-05MG M2iwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIflbGZKSzVyPUCuOVgxPTNizszN M{\CN3NCVkeHUh?=
MKN1 M4nBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGCxRWFKSzVyPUCuOVg4QDNizszN M3vKZnNCVkeHUh?=
ES3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPxb5Z7UUN3ME2wMlU6OTJ2IN88US=> NEfkcXRUSU6JRWK=
OVCAR-3 NUfrVlliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTocoE{UUN3ME2wMlU6OzRzIN88US=> NYG0VXN6W0GQR1XS
ACHN M{HVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonjTWM2OD1yLk[wOVY6KM7:TR?= M3XJOXNCVkeHUh?=
SW872 NV36W21LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHkTWM2OD1yLk[wO|Y{KM7:TR?= MYjTRW5ITVJ?
CP66-MEL NImyOYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwNkC5Olkh|ryP NXv5R|BiW0GQR1XS
NCI-H661 NF;Qc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwNkGxNFQh|ryP M1m3SHNCVkeHUh?=
UACC-893 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\0fWdKSzVyPUCuOlM3QDFizszN MnWwV2FPT0WU
JVM-3 M3qz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fzS2lEPTB;MD62N|gxPCEQvF2= NWi5eYt7W0GQR1XS
SF268 NWrERmJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwNkSzOFkh|ryP MVnTRW5ITVJ?
OCI-AML2 M3vlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NECzdWpKSzVyPUCuOlU{QTdizszN MmLoV2FPT0WU
RPMI-8226 NFHTeHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHDeY5bUUN3ME2wMlY3OzJ|IN88US=> MWXTRW5ITVJ?
MKN28 M4HBcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPl[mdKSzVyPUCuOlY3OjRizszN MmfUV2FPT0WU
MDA-MB-453 M4jtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f5OmlEPTB;MD62O|E5KM7:TR?= M1m2ZnNCVkeHUh?=
BV-173 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f1fGlEPTB;MD62PFY4QSEQvF2= MluwV2FPT0WU
NCI-H358 NUfpbY9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzIZZI{UUN3ME2wMlY5PzJ4IN88US=> M2\VeHNCVkeHUh?=
NCI-H1651 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi5PYxKSzVyPUCuO{DPxE1? Mkj2V2FPT0WU
MDA-MB-415 NUfhPIU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPMb4ZKSzVyPUCuO|A5OjlizszN MnSxV2FPT0WU
8305C NEPjZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDtTWM2OD1yLkeyOFk5KM7:TR?= MYnTRW5ITVJ?
EFM-19 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPQTWM2OD1yLkezOlcyKM7:TR?= M{fPfHNCVkeHUh?=
RERF-LC-MS NV3CTnIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\XTWM2OD1yLke0OlE{KM7:TR?= M{X1RnNCVkeHUh?=
A388 M1TWfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDDTWM2OD1yLke2OFY4KM7:TR?= MX7TRW5ITVJ?
GI-ME-N M2T1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3aTWM2OD1yLke3NlM2KM7:TR?= MmP1V2FPT0WU
IGR-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HoTWlEPTB;MD63PVA1OyEQvF2= NYXoNW1pW0GQR1XS
LNCaP-Clone-FGC NWnHfVBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PKRmlEPTB;MD64NFAxPCEQvF2= NWjjTmx3W0GQR1XS
SK-MEL-3 NHfYO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP4[VR5UUN3ME2wMlgyPTB6IN88US=> MUnTRW5ITVJ?
UACC-257 MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwOEKyN|Eh|ryP MnrWV2FPT0WU
OE33 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jZWGlEPTB;MD64OVExOSEQvF2= MUjTRW5ITVJ?
QIMR-WIL M1KyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwOEWxOFEh|ryP MkG4V2FPT0WU
NCI-H2009 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwOEWzNVEh|ryP NWr0dYh3W0GQR1XS
NCI-H522 NYjkOHJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTFSWNrUUN3ME2wMlg4Pzh|IN88US=> MY\TRW5ITVJ?
Saos-2 NFnOZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz0TWM2OD1yLki3PFcyKM7:TR?= MlG3V2FPT0WU
NB17 MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL1PVRoUUN3ME2wMlg5ODJ3IN88US=> NUjRcWRPW0GQR1XS
D-392MG NEnTWmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPOdpNlUUN3ME2wMlg6OzV4IN88US=> NYLHU5lZW0GQR1XS
SHP-77 MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrSTWM2OD1yLkmwOFg2KM7:TR?= NUDs[JRiW0GQR1XS
SK-MEL-30 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnvW4pKSzVyPUCuPVEyQDVizszN NV7YfIxPW0GQR1XS
GCIY MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHraVopKSzVyPUCuPVE5PDNizszN NVXXNVRSW0GQR1XS
HCC70 Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq1UI1KSzVyPUCuPVIxPTlizszN MnvpV2FPT0WU
LU-65 Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwOUK1PVEh|ryP MVLTRW5ITVJ?
NCI-H1563 NGjDNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInEfm9KSzVyPUCuPVQ5PjVizszN M3\OOHNCVkeHUh?=
KURAMOCHI M1PPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwOUWxPVIh|ryP NH\UUm9USU6JRWK=
PA-1 M3ewZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TtVGlEPTB;MD65OVQzPCEQvF2= NX3kfmJjW0GQR1XS
NOS-1 NHLUSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPrN3lKSzVyPUCuPVc1QDlizszN NWjUdYZ4W0GQR1XS
NCI-H69 NVvRfI9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwOUe2N|Qh|ryP M{\ZN3NCVkeHUh?=
KYSE-450 MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPlT2lKSzVyPUCuPVg3OjZizszN MVXTRW5ITVJ?
8505C M1zzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy4c5BrUUN3ME2wMlk6QTh{IN88US=> NHPQcnRUSU6JRWK=
TGBC24TKB M1\kVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTxb|lKSzVyPUGuNFAxQDRizszN NGjFeldUSU6JRWK=
PFSK-1 M17PNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfK[ox6UUN3ME2xMlAyPDJ6IN88US=> MXTTRW5ITVJ?
EKVX MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInIUGVKSzVyPUGuNFMyOjFizszN M4TiXnNCVkeHUh?=
RCM-1 NW\aRplkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fCW2lEPTB;MT6wOVUxPyEQvF2= M1nDSXNCVkeHUh?=
SW900 Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\xNGhiUUN3ME2xMlA4QDNizszN MkXzV2FPT0WU
D-542MG NVXqcpcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HQTWlEPTB;MT6wO|g2PSEQvF2= NIjJeWFUSU6JRWK=
SK-PN-DW NHrWb|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTFwMUCwOVYh|ryP MXjTRW5ITVJ?
NCI-H727 M3T5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3EToZKSzVyPUGuNVAyPTRizszN M{i2U3NCVkeHUh?=
SW837 NXPwdng3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX2TWM2OD1zLkGwPVU1KM7:TR?= NUTwZWdvW0GQR1XS
BT-20 NF;JcnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHvWnhKSzVyPUGuNVEzODRizszN MYjTRW5ITVJ?
RH-18 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWm0NmtIUUN3ME2xMlE{OTB|IN88US=> M2DjbnNCVkeHUh?=
TE-12 NX3lWWczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTFwMUOzN|Mh|ryP NUfqbZBOW0GQR1XS
NB10 MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\ZbYdKSzVyPUGuNVM{PDRizszN MVfTRW5ITVJ?
AU565 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nGTGlEPTB;MT6xOVk4OyEQvF2= NGTXZYlUSU6JRWK=
OAW-42 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwMUizNFYh|ryP NYi4dJlvW0GQR1XS
DJM-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWOwTFdSUUN3ME2xMlE6QDhzIN88US=> MYHTRW5ITVJ?
HH M3v2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzSZmpOUUN3ME2xMlI{QDNzIN88US=> MYPTRW5ITVJ?
LAMA-84 MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFwMkezPVQh|ryP MnuyV2FPT0WU
KNS-42 NGnWcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTCTWM2OD1zLkOwNlk3KM7:TR?= M2\2cHNCVkeHUh?=
NCI-H2052 MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDxO3RNUUN3ME2xMlMxPTB5IN88US=> NVu4fZhFW0GQR1XS
MLMA NVXrcmFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnVNZNNUUN3ME2xMlMzPDB5IN88US=> Mon3V2FPT0WU
NB12 Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTFwM{W2N|Yh|ryP MYHTRW5ITVJ?
NCI-H1838 NYfmPGxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf2TWM2OD1zLkO2N|A3KM7:TR?= MoPjV2FPT0WU
NCI-H526 NWXlVVVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGS5fZpKSzVyPUGuN|c5PTNizszN MW\TRW5ITVJ?
LS-123 MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXXZ5pZUUN3ME2xMlM6ODl2IN88US=> M2jaS3NCVkeHUh?=
HDLM-2 MoD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTFwM{myO|Eh|ryP M{K3V3NCVkeHUh?=
MC-IXC NE\zTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwNEKzO|Eh|ryP NILzcZBUSU6JRWK=
HCT-15 M4LWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYewdoNvUUN3ME2xMlQ{ODZ6IN88US=> NWnUWo8yW0GQR1XS
NCI-H596 NVjIdGtiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT5UZc4UUN3ME2xMlQ2ODZzIN88US=> MWfTRW5ITVJ?
ZR-75-30 NXTtZnRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwNEewPFIh|ryP MYDTRW5ITVJ?
A704 NUXwSWNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoOyTWM2OD1zLk[2OVY{KM7:TR?= MkXlV2FPT0WU
OVCAR-4 Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGwTWM2OD1zLk[5OlA4KM7:TR?= NXPEWGZRW0GQR1XS
SW1417 NGnGOodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD1TWM2OD1zLkeyPFQ6KM7:TR?= MoDaV2FPT0WU
CAS-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrqTWM2OD1zLkezPVM3KM7:TR?= NFL5T2tUSU6JRWK=
IST-SL1 MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LDVWlEPTB;MT63PVc2QSEQvF2= NGPiTW9USU6JRWK=
A253 NF\ONYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTFwOEKyN|kh|ryP NVT1d|hCW0GQR1XS
EW-16 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\2N|Q3UUN3ME2xMlgzQDd3IN88US=> NFTTfHdUSU6JRWK=
SK-NEP-1 Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\B[HRZUUN3ME2xMlg3QTh6IN88US=> MlfOV2FPT0WU
NCI-H226 NE\mToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXMTWM2OD1zLki5N|U6KM7:TR?= M4niT3NCVkeHUh?=
HOP-92 MmO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu0TWM2OD1zLkm2NFk6KM7:TR?= MmPQV2FPT0WU
NCI-H441 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTZTWM2OD1{LkCyN|M4KM7:TR?= NFfGO3lUSU6JRWK=
LU-139 MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJwMEOxNVQh|ryP MoL0V2FPT0WU
SJRH30 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17oZmlEPTB;Mj6wOFI2OyEQvF2= MXnTRW5ITVJ?
MG-63 M3u4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIiyeWRKSzVyPUKuNVQyOTFizszN NWDP[ohuW0GQR1XS
NH-12 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnPcpBpUUN3ME2yMlE2ODB4IN88US=> MlLkV2FPT0WU
NB7 M1zDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzHelk{UUN3ME2yMlE6Pjd|IN88US=> MmrmV2FPT0WU
LB771-HNC NYS1[lZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITUTmJKSzVyPUKuNlA2QTVizszN MUTTRW5ITVJ?
HCC1569 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoruTWM2OD1{LkK0OVg{KM7:TR?= MV;TRW5ITVJ?
D-283MED MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJwMkS3PFIh|ryP M{DT[3NCVkeHUh?=
J-RT3-T3-5 M1;KXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfjUpF4UUN3ME2yMlI2OzVzIN88US=> NW\xcotYW0GQR1XS
ATN-1 NEGzNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXZTWM2OD1{LkOzNFgzKM7:TR?= MkjqV2FPT0WU
HCC1954 MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjRUmtKSzVyPUKuN|Q1ODhizszN NFPkeG9USU6JRWK=
SCC-15 MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nPcWlEPTB;Mj6zPVMyOiEQvF2= NVrtWpNEW0GQR1XS
COLO-668 M1HsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;BT4NKSzVyPUKuOFMzKM7:TR?= NF3pVVhUSU6JRWK=
LB373-MEL-D MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVS0PXp2UUN3ME2yMlU1Pjd5IN88US=> NHize45USU6JRWK=
no-10 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPjSZlSUUN3ME2yMlU1QTR5IN88US=> MnnlV2FPT0WU
HT-1197 MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXqemozUUN3ME2yMlY{OTh6IN88US=> Mk[wV2FPT0WU
DU-145 NH[1cJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvEbWFKSzVyPUKuO|kyPjJizszN NEXsfIpUSU6JRWK=
SK-N-AS M3XqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn1TWM2OD1{Lki0OlkzKM7:TR?= NIjuVoRUSU6JRWK=
MOLT-4 M3HIRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojlTWM2OD1{Lki1N|IzKM7:TR?= NWjYcIxGW0GQR1XS
EW-22 Ml;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJwOUK4OFEh|ryP M3TqNnNCVkeHUh?=
DB M4DrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3GxTmlEPTB;Mj65O|c2QSEQvF2= MnvuV2FPT0WU
HL-60 NVHLT3RCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnpfJdJUUN3ME2zMlA1Ozd4IN88US=> Mn35V2FPT0WU
SK-N-DZ NV7QfZBDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7rTWM2OD1|LkC1NFc2KM7:TR?= MYLTRW5ITVJ?
NY MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTNwMEi1OFIh|ryP NWHsdVV3W0GQR1XS
T47D MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnJWIlKSzVyPUOuNVA2PThizszN MnzzV2FPT0WU
NCI-H2029 NGrUdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTNwMkK0O|ch|ryP NYLw[XhsW0GQR1XS
KARPAS-299 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrHTWM2OD1|LkK2NFI4KM7:TR?= NEjaRZNUSU6JRWK=
KM-H2 NUm0RWRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO2NmVKSzVyPUOuN|A3QCEQvF2= M1ey[HNCVkeHUh?=
CHP-134 MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmP0TWM2OD1|LkS3N|kh|ryP Ml3oV2FPT0WU
22RV1 MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUi1[IxkUUN3ME2zMlQ6OTZ6IN88US=> Ml;CV2FPT0WU
NB5 M{PCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfwNmNKSzVyPUOuOVA3QDlizszN NWjsO21VW0GQR1XS
CW-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LNfWlEPTB;Mz61OVMyPCEQvF2= NEf1WXJUSU6JRWK=
EFO-21 NXviWHlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTNwNU[5OEDPxE1? NHPQSmxUSU6JRWK=
HuH-7 MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PEV2lEPTB;Mz61PFQyPCEQvF2= NVTTU2RRW0GQR1XS
ALL-PO NYjsS4RvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3KyemlEPTB;Mz62NlM{PSEQvF2= NFLveZhUSU6JRWK=
EM-2 M37jWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\1TWM2OD1|Lk[5NFEyKM7:TR?= NVL1OWdKW0GQR1XS
KLE NWK4WHE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXtTWM2OD1|LkezNFI6KM7:TR?= NEDsSHFUSU6JRWK=
NEC8 NUTFbJBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTNwOUG4NFgh|ryP NXHPXlhSW0GQR1XS
KP-N-YN MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoniTWM2OD1|LkmzOFc3KM7:TR?= MVfTRW5ITVJ?
SK-MEL-1 M{T1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;MdWlEPTB;ND6wN|UyQCEQvF2= MVPTRW5ITVJ?
CAL-54 MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTRwMEW5NUDPxE1? MVTTRW5ITVJ?
MS-1 NIfoeFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4CyXmlEPTB;ND6xOlE2PSEQvF2= NFfzTVZUSU6JRWK=
NCI-H209 NWm5T4VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTRwMkm5PVkh|ryP M4joUnNCVkeHUh?=
NOMO-1 NUHVTJFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTRwM{KxN|Eh|ryP Mn2wV2FPT0WU
RPMI-2650 M4XS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PJeWlEPTB;ND6zOlMzPyEQvF2= NV;2TW5JW0GQR1XS
NCI-H810 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTRwM{m3N|Yh|ryP NYftOohjW0GQR1XS
Ca9-22 NXfUemp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTRwNEW2PVEh|ryP MlrwV2FPT0WU
ES4 M{fXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33jd2lEPTB;ND60O|A6PSEQvF2= MXjTRW5ITVJ?
ES6 M{XsU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTRwNEm2OVch|ryP NH\PPWxUSU6JRWK=
DMS-114 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPDT3lKSzVyPUSuOVQ3QTFizszN M{mySnNCVkeHUh?=
ONS-76 M4\rdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPkfnFKSzVyPUSuOVc6PSEQvF2= M2ruUnNCVkeHUh?=
K-562 Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTRwN{O4NVQh|ryP M2DxXnNCVkeHUh?=
MHH-NB-11 M{Xsemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrrTWM2OD12Lke1OFYyKM7:TR?= NWXlUYkzW0GQR1XS
Calu-3 MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj5TWM2OD12Lke4OVQ5KM7:TR?= MYHTRW5ITVJ?
HT55 M4jqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLpTpBKSzVyPUSuPFQ2PDVizszN MVnTRW5ITVJ?
SK-N-FI M3XZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkW4TWM2OD12Lki1NFA6KM7:TR?= MnLRV2FPT0WU
ES1 MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTRwOE[wOVch|ryP MmfQV2FPT0WU
SF126 NWDNV5NGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzpTWM2OD12LkmzNVg1KM7:TR?= NVnUR2ZQW0GQR1XS
ES5 MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjtRmh{UUN3ME21MlEzPDJ5IN88US=> MVvTRW5ITVJ?
LoVo MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7TTWM2OD13LkG1PFcyKM7:TR?= NGDuSFBUSU6JRWK=
SNU-387 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnviTWM2OD13LkOyN|M6KM7:TR?= MXHTRW5ITVJ?
C8166 NHvDW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W0cGlEPTB;NT6zOlM{QSEQvF2= NGnRVHRUSU6JRWK=
LS-1034 M3r6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrJTWM2OD13LkSyN|A4KM7:TR?= MoXkV2FPT0WU
GR-ST MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrTTWM2OD13LkWyNlAyKM7:TR?= NHywNo5USU6JRWK=
NCI-H1092 M1e0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTVwN{K4OFMh|ryP NWTzc2JzW0GQR1XS
647-V Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjYUplKSzVyPUWuO|Q4ODZizszN NYLiWWszW0GQR1XS
EW-13 M3vMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XRfWlEPTB;NT63OlYzPyEQvF2= NGLIco9USU6JRWK=
KGN MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUi1fVR2UUN3ME22MlA6QTJzIN88US=> NETofFNUSU6JRWK=
D-423MG NEDOSXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nMUGlEPTB;Nj60NFI5PCEQvF2= MnroV2FPT0WU
ECC10 MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTdwMUCxNFEh|ryP NWjVR411W0GQR1XS
TE-5 NVPWZVVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkT2TWM2OD15LkSxNlk5KM7:TR?= MVnTRW5ITVJ?
P12-ICHIKAWA M3\odmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTdwNEW1NlMh|ryP Mn3GV2FPT0WU
NCI-H82 MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTdwNEW3NFEh|ryP MofjV2FPT0WU
NCI-H1993 NV21bXNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDTPGlxUUN3ME23Mlg{ODZ|IN88US=> MW\TRW5ITVJ?
RH-1 NHjXeI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[xTWM2OD15Lki1NlQ1KM7:TR?= NXuwc2c4W0GQR1XS
SW948 NXzJSXJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknnTWM2OD15Lkm2NFQ6KM7:TR?= M2TJ[3NCVkeHUh?=
CAL-33 NWfnXWdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXHTWM2OD15Lkm5PVM5KM7:TR?= NYXO[GNqW0GQR1XS
U-266 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vmb2lEPTB;OD6xOVc4PyEQvF2= NHH5cpRUSU6JRWK=
CAL-72 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fNXWlEPTB;OD6yNFMzKM7:TR?= MnnhV2FPT0WU
SNU-423 NFPmVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3LTWM2OD17LkO2OlY3KM7:TR?= NFfWW5FUSU6JRWK=
KG-1 MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1O3UGlEPTB;OT61PFQ2PiEQvF2= M3;XT3NCVkeHUh?=
HCC1395 NWPVNFF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPXXopKSzVyPUmuPVI{PTJizszN M{LRPXNCVkeHUh?=
BE-13 M3LHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO4OYw2UUN3ME2xNE45QDl{IN88US=> MWHTRW5ITVJ?
MKN7 M{fkfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTFyLkm3OlUh|ryP MWHTRW5ITVJ?
697 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfMTWM2OD1zMT6xOFczKM7:TR?= Ml76V2FPT0WU
LU-135 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTFzLkKzNFch|ryP M4LxXnNCVkeHUh?=
ES7 Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTFzLkOzNVMh|ryP Mlq5V2FPT0WU
SK-HEP-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnKwTWM2OD1zMT63OlQ3KM7:TR?= MVfTRW5ITVJ?
BEN MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnEU2ZKSzVyPUGxMlg2OSEQvF2= M4KxPHNCVkeHUh?=
NCI-H1770 MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjMTVBKSzVyPUGyMlEzPiEQvF2= MkfsV2FPT0WU
SW13 NH3oSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\ST4pKSzVyPUGyMlE2PDFizszN MnPaV2FPT0WU
MZ1-PC M4\uR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r4XGlEPTB;MUKuOVQ2OiEQvF2= M{H5cXNCVkeHUh?=
Mo-T NEHGN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF{Lke0NlEh|ryP MYXTRW5ITVJ?
HLE NV62OoVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fnUWlEPTB;MUKuPFIyPSEQvF2= M2XENnNCVkeHUh?=
RCC10RGB NXry[mZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF|Lk[3NUDPxE1? M{joOnNCVkeHUh?=
COLO-320-HSR NVvxWVFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX4eJVKSzVyPUGzMlc{QDFizszN NVz3U5VpW0GQR1XS
BHT-101 NXS1dIUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF|LkizOFUh|ryP MVXTRW5ITVJ?
OCUB-M Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvKZWdVUUN3ME2xOE4yPjB{IN88US=> Mn3wV2FPT0WU
MEG-01 NYrVemZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF2LkO3NFgh|ryP M4LzbnNCVkeHUh?=
RS4-11 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHRNoRmUUN3ME2xOE44PDJizszN NV64eoM3W0GQR1XS
MN-60 NXvzXpNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVva[2ZJUUN3ME2xOE44QDl2IN88US=> MWjTRW5ITVJ?
NCI-H1304 NHLyPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHIUIhMUUN3ME2xOU4xPDJ3IN88US=> NXrEXVNpW0GQR1XS
Ramos-2G6-4C10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK0WXRiUUN3ME2xOU4xPThzIN88US=> MVLTRW5ITVJ?
NCI-H2342 NWjrdGFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWm1SIc4UUN3ME2xOU4zODR2IN88US=> M{DXUnNCVkeHUh?=
LAN-6 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjmR|BKSzVyPUG1MlQ1OTRizszN MoLjV2FPT0WU
JVM-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS1fIJ4UUN3ME2xOU42PzR6IN88US=> NXXCOlJFW0GQR1XS
P30-OHK M{nKU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3ve3hFUUN3ME2xOk4xPjF2IN88US=> MoH3V2FPT0WU
C-33-A MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13tT2lEPTB;MU[uOlIyPCEQvF2= NUTvR4IxW0GQR1XS
RPMI-8866 NXz4cIxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\iUWlEPTB;MU[uPFQ6PiEQvF2= NHrBUGRUSU6JRWK=
NCI-H630 Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrNVZh[UUN3ME2xOk45PTN5IN88US=> NGnwfo5USU6JRWK=
KYSE-140 M3;Se2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIq1e|lKSzVyPUG3MlIxOjhizszN M3WxSnNCVkeHUh?=
T84 NHTWcWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmWwTWM2OD1zOD64Olk2KM7:TR?= MXvTRW5ITVJ?
KU-19-19 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHObVZKSzVyPUG4Mlk3ODhizszN M2nKT3NCVkeHUh?=
BALL-1 M2rxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTF7LkOzPVkh|ryP MX\TRW5ITVJ?
Calu-6 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInkcWFKSzVyPUG5MlQ6OiEQvF2= MUXTRW5ITVJ?
EGI-1 MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjaW3NKSzVyPUG5MlU6QCEQvF2= NYnHXVZXW0GQR1XS
MFH-ino M320Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHz5T2hKSzVyPUG5Mlc1PTRizszN M2PTRnNCVkeHUh?=
GB-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjzSoRKSzVyPUKwMlM2OzVizszN NX7NXpJMW0GQR1XS
NCI-H1693 M1nLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz0TWM2OD1{MD62OVA2KM7:TR?= MoT5V2FPT0WU
SW1116 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPlTWM2OD1{MD65N|YzKM7:TR?= MUXTRW5ITVJ?
H-EMC-SS M3\4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rLSGlEPTB;MkKuNFQ2KM7:TR?= M4PJR3NCVkeHUh?=
D-502MG M2mxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zhO2lEPTB;MkKuPFI3OSEQvF2= NED3cXhUSU6JRWK=
IA-LM NXHEb45HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLVdIRKSzVyPUKzMlI1QTNizszN MmqzV2FPT0WU
SW1463 NIfV[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3JbFRKSzVyPUKzMlc6KM7:TR?= NFHieo1USU6JRWK=
JAR NGnQc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJ2LkOyPVMh|ryP MYPTRW5ITVJ?
HT MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrxNYJKSzVyPUK0MlQ4PTNizszN NYTBSG9RW0GQR1XS
LCLC-103H MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJ2Lki0OFkh|ryP M1y2[3NCVkeHUh?=
SNU-449 MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ2Lki3OFEh|ryP MY\TRW5ITVJ?
KE-37 M13Dd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M330S2lEPTB;MkWuNFkzQCEQvF2= MYXTRW5ITVJ?
NCI-H1623 M3PhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFz6WnVKSzVyPUK3MlE{ODNizszN MknyV2FPT0WU
MOLT-13 M{XyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;MTWM2OD1{Nz6zOVE3KM7:TR?= Mlr2V2FPT0WU
COLO-741 NY\aTodyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTNzLkOzN|Mh|ryP NH\LSWpUSU6JRWK=
NB6 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTN{LkK4O|Yh|ryP MlXBV2FPT0WU
MOLT-16 MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fueGlEPTB;M{OuNFA2PSEQvF2= NWnMWndxW0GQR1XS
IST-MES1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTN2LkC1OFEh|ryP NEDCcGdUSU6JRWK=
A4-Fuk NFrJVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTN3LkC2OkDPxE1? NYnCPIVRW0GQR1XS
CAL-85-1 M2roNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn[4TWM2OD1|NT6yPFE4KM7:TR?= MmW0V2FPT0WU
CCRF-CEM NXzRN2cxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XUcWlEPTB;M{euNVU{PiEQvF2= NH[5[o9USU6JRWK=
HAL-01 NWjFRZVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTOTmpMUUN3ME2zPE41QDh7IN88US=> MUfTRW5ITVJ?
HEL MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfNTWM2OD12Mz6zOFA6KM7:TR?= NEO2[YFUSU6JRWK=
EW-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHmxUndKSzVyPUSzMlQ4PjhizszN M3LidnNCVkeHUh?=
MDA-MB-231 NH3MTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITYbHhKSzVyPUS1MlEyQTlizszN MWLTRW5ITVJ?
ABC-1 NYPodFdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHrToxKSzVyPUS2Mlg2OzhizszN NYPpOWRvW0GQR1XS
NCI-H446 M3Xjbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTR6LkWwOVgh|ryP M4r5O3NCVkeHUh?=
MHH-PREB-1 NF;RVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[0NGlEPTB;NEmuOlAxPyEQvF2= NEXQV3JUSU6JRWK=
DOHH-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fEcWlEPTB;NEmuOlY2PiEQvF2= NE\6bHdUSU6JRWK=
GCT M4\HT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DpWmlEPTB;NEmuOlk4PiEQvF2= M2W5bnNCVkeHUh?=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
α-Synuclein / HSP90 / HSP70 / HSP32 / αB-Crystallin; 

PubMed: 20090920     


Immunoblot analysis of heat shock protein induction. Cells were treated with 17-AAG (1–200 nM, 24 h), or subjected to heat shock (HS: 44°C, 30 min, 24 h recovery) or to MG-132 (MG: 1 µM, 24 h). Cell lysates were prepared and immunoblot analysis was carried out with antibodies against the individual proteins as indicated on the right. Co, untreated control.

EGFR / PDGFR / AKT / MAPK / c-RAS; 

PubMed: 18682579     


17-AAG promotes the degradation of HSP90 client proteins that are involved in the pathology of glioblastoma multiforme (GBM). Glioma cell lines were treated with increasing concentrations of 17-AAG for 48 h, and protein lysates were run on Western blots. HSP90 client proteins known to be involved in gliomagenesis showed degradation while nonclient proteins remained unaffected by 17-AAG treatment.

pAKT / pMAPK / pRb; 

PubMed: 18682579     


The phosphorylated states of signaling proteins involved in glioma growth are also affected by 17-AAG treatment.

Cleaved PARP / Survivin; 

PubMed: 18827603     


Western analysis of expression levels of cleaved PARP and Survivin in MM cell lines. β-Actin served as loading control.

LATS1 / p-LATS1 / YAP / CTGF; 

PubMed: 25712415     


Effects of 17-AAG on the expression of LATS1, p-LATS1, YAP and CTGF.  The expression levels of YAP and CTGF proteins, indicated by Western blot assay, were down-regulated, while LATS1 was upregulated in a dose-dependent manner in 17-AAG treated groups compared to the untreated group.

20090920 18682579 18827603 25712415
Immunofluorescence
STAT3; 

PubMed: 27279418     


Effects of 17-AAG on STAT3 expression of H446 cells. (A) Control group; (B) 3.125 mg/l; (C) 6.25 mg/l. 17-AAG, 17-allylamino-17-demethoxygel-danamycin; STAT3, signal transducer and activator of transcription 3; DAPI, 4′,6-diamidino-2-phenylindole.

YAP / TAZ; 

PubMed: 25290150     


Reduction in cytoplasmic distribution accompanied by increased nuclear localization of YAP/TAZ was more apparent in cells treated with 45 nM 17-AAG (red channel for YAP/TAZ and blue channel for nucleus). Statistical comparisons were performed using one-way Kruskal-Wallis multiple comparison, ***p<0.001 compared with control (0 nM).

β-catenin / E-cadherin; 

PubMed: 25290150     


Co-localization of β-catenin (Red) and E-cadherin (Green) was observed at the cell-cell junctions (white arrows) both in siCtrl and siCTGF cells after 17-AAG treatment. Scale bar is 20 µm.

27279418 25290150
Growth inhibition assay
Cell viability; 

PubMed: 18682579     


17-AAG inhibits the growth of human glioma cell lines. Human glioma cell lines and a nontumorigenic fibroblast cell line were treated with increasing concentrations of 17-AAG for 4 days, and the effect on cell growth was assessed by a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. The 50% inhibitory concentration (IC50) of all glioma cell lines ranged from 0.05 to 0.5 μM 17-AAG, as compared to 1.5 μM for the nontumorigenic cells.

18682579
In vivo 17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. [1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. [2]

Protocol

Kinase Assay:[1]
- Collapse

Hsp90 binding assays:

Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:[1]
- Collapse
  • Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 5 days
  • Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells is subtracted. Percentage of viable cells = (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6
  • Dosages: ~50 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (170.73 mM)
Ethanol 5 mg/mL (8.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+corn oil
For best results, use promptly after mixing. 		10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 585.69
Formula

C31H43N3O8
CAS No. 75747-14-7
Storage powder
in solvent
Synonyms CP127374,NSC-330507, KOS 953
Smiles COC1CC(C)CC2=C(NCC=C)C(=O)C=C(NC(=O)C(=C\C=C/C(OC)C(OC(N)=O)/C(=C/C(C)C1O)C)\C)C2=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00103272 Terminated Drug: tanespimycin|Drug: bortezomib Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia National Cancer Institute (NCI) April 2005 Phase 1
NCT00098488 Terminated Drug: tanespimycin|Biological: rituximab B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia National Cancer Institute (NCI) April 2005 Phase 1
NCT00118248 Completed Drug: tanespimycin Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma National Cancer Institute (NCI) December 2004 Phase 2
NCT00098423 Completed Drug: tanespimycin|Drug: cytarabine Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes National Cancer Institute (NCI) November 2004 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?

  • Answer:

    17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

selleck catalog

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

  • Selective HSP90 Inhibitor

    NVP-BEP800 : HSP90β-selective, IC50=58 nM.

  • Most Potent HSP90 Inhibitor

    KW-2478 : HSP90, IC50=3.8 nM.

  • HSP90 Inhibitor in Clinical Trial

    17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.

  • Newest HSP90 Inhibitor

    XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (e.g. HSP90) Products

  • PU-H71 New

    PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.

  • KNK437 New

    KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.

  • VER155008 New

    VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.

  • Luminespib (NVP-AUY922)

    Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.

  • Ganetespib (STA-9090)

    Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

  • Alvespimycin (17-DMAG) HCl

    Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

    Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.

  • Geldanamycin

    Geldanamycin is a natural existing HSP90 inhibitor with Kd of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.

  • HSP990 (NVP-HSP990)

    NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

    Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.

  • Elesclomol (STA-4783)

    Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

  • Onalespib (AT13387)

    Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Tags: buy Tanespimycin (17-AAG) | Tanespimycin (17-AAG) supplier | purchase Tanespimycin (17-AAG) | Tanespimycin (17-AAG) cost | Tanespimycin (17-AAG) manufacturer | order Tanespimycin (17-AAG) | Tanespimycin (17-AAG) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID